DAFTAR PUSTAKA

1. World Health Organization. Covid-19. 2021 [cited 2022 Jan 5]. Available from: https://covid19.who.int/

2. Yesudhas D, Srivastava A, Gromiha MM. COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics. Infection. 2021;49(2). Available from: https://doi.org/10.1007/s15010-020-01516-2

3. World Health Organization. Covid-19. 2020. Available from: https://covid19.who.int/

4. Gugus Tugas Percepatan Penanganan COVID-19. Data Sebaran . Available from: https://www.covid19.go.id/

5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229).

6. Satria RMA, Tutupoho RV, Chalidyanto D. Analisis Faktor Risiko Kematian dengan Penyakit Komorbid Covid-19. J Keperawatan Silampari. 2020;4(1).

7. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18).

8. Liu ZM, Li JP, Wang SP, Chen DY, Zeng W, Chen SC, et al. Association of procalcitonin levels with the progression and prognosis of hospitalized patients with COVID-19. Int J Med Sci. 2020;17(16).

9. Berger JS, Kunichoff D, Adhikari S, Ahuja T, Amoroso N, Aphinyanaphongs Y, et al. Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients with COVID-19. Arterioscler Thromb Vasc Biol. 2020;

10. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Japan Acad Ser B Phys Biol Sci . 2017;93(7). Available from: https://dx.doi.org/10.2183/pjab.93.027

11. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3). Available from: https://dx.doi.org/10.1038/s41422-020-0282-0

12. Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus Umifenovir for COVID-19: A randomized clinical trial. medRxiv . 2020; Available from: https://dx.doi.org/10.1101/2020.03.17.20037432

13. Kocayiğit H, Özmen Süner K, Tomak Y, Demir G, Yaylacı S, Dheir H, et al. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19. J Clin Pharm Ther . 2021;46(2). Available from: https://dx.doi.org/10.1111/jcpt.13305

14. Almoosa Z, Saad M, Qara S, Mustafa M, Mansour A, Alshab D, et al. Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study. J Infect Public Health . 2021;14(9). Available from: https://dx.doi.org/10.1016/j.jiph.2021.08.022

15. Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R. The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials. medRxiv . 2021; Available from: https://dx.doi.org/10.1038/s41598-021-90551-6

16. Damle B, Vourvahis M, Wang E, Leaney J, Corrigan B. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19. Clin Pharmacol Ther. 2020;108(2). Available from: https://dx.doi.org/10.1002/cpt.1857

17. Li C, Zu S, Deng YQ, Li D, Parvatiyar K, Quanquin N, et al. Azithromycin protects against Zika virus infection by upregulating virus-induced type I and III interferon responses. Antimicrob Agents Chemother. 2019;63(12). Available from: https://dx.doi.org/10.1128/AAC.00394-19

18. Albani F, Fusina F, Giovannini A, Ferretti P, Granato A, Prezioso C, et al. Impact of azithromycin and/or hydroxychloroquine on hospital mortality in covid-19. J Clin Med. 2020;9(9). Available from: https://dx.doi.org/10.3390/jcm9092800

19. Mangkuliguna G, Glenardi, Natalia, Pramono LA. Efficacy and safety of azithromycin for the treatment of covid-19: A systematic review and meta-analysis. Tuberc Respir Dis (Seoul). 2021;84(4). Available from: https://dx.doi.org/10.4046/TRD.2021.0075

20. Susilo A. Coronavirus Disease 2019: Tinjauan Literatur Terkini, Jurnal Penyakit Dalam Indonesia. J Penyakit Dalam Indones . 2020;7(1). Available from: http://dx.doi.org/10.7454/jpdi.v7i1.415

21. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med . 2020;382(13). Available from: https://dx.doi.org/10.1056/nejmoa2001316

22. World Health Organization. Covid-19 Public Health Emergency og International Concern (PHEIC) . 2020. Available from: https://www.who.int/publications/m/item/covid-19-public-health-emergency-of-international-concern-(pheic)-global-research-and-innovation-forum

23. Viceconte G, Petrosillo N. Covid-19 R0: Magic number or conundrum? Infect Dis Rep . 2020;12(1). Available from: https://dx.doi.org/10.4081/idr.2020.8516

24. Kemenkes RI. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19). Germas. 2020.

25. Du Z, Xu X, Wu Y, Wang L, Cowling BJ, Meyers LA. Serial interval of COVID-19 among publicly reported confirmed cases. Emerg Infect Dis . 2020;26(6). Available from: https://dx.doi.org/10.3201/EID2606.200357

26. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res . 2020;24. Available from: https://dx.doi.org/10.1016/j.jare.2020.03.005

27. Riedel S, Hobden JA, Miller S, Morse SA, Mietzner TA, Detrick B, et al. Coronaviruses. In: Jawetz, Melnick, & Adelberg's Medical Microbiology. 28th Ed. New York: McGraw-Hill Education/Medical; 2019. p. 617.

28. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group. bioRxiv . 2020; Available from: https://dx.doi.org/10.1101/2020.02.07.937862

29. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. J Chinese Med Assoc . 2020;83(3). Available from: https://dx.doi.org/10.1097/JCMA.0000000000000270

30. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol . 2020;215. Available from: https://dx.doi.org/10.1016/j.clim.2020.108427

31. Rabi FA, Al Zoubi MS, Al-Nasser AD, Kasasbeh GA, Salameh DM. Sars-cov-2 and coronavirus disease 2019: What we know so far. Pathogens . 2020;9(3). Available from: https://dx.doi.org/10.3390/pathogens9030231

32. Thomas S. The structure of the membrane protein of sars-cov-2 resembles the sugar transporter semisweet. Pathog Immun . 2020;5(1). Available from: https://dx.doi.org/10.20411/pai.v5i1.377

33. Schoeman D, Fielding BC. Coronavirus envelope protein: Current knowledge. Virol J . 2019;16(1). Available from: https://dx.doi.org/10.1186/s12985-019-1182-0

34. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet . 2020;395(10226). Available from: https://dx.doi.org/10.1016/S0140-6736(20)30360-3

35. Wang Z, Qiang W, Ke H. A Handbook of 2019-nCoV Pneumonia Control and Prevention. Hubei Science and technology press. 2020.

36. Li LQ, Huang T W. 2019 novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of meta-analysis. J Med Virol . 2020;92. Available from: http://dx.doi.org/10.1002/jmv.25757

37. Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci U S A . 2009;106(14). Available from: https://dx.doi.org/10.1073/pnas.0809524106

38. Millet JK, Whittaker GR. Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis. Virus Res . 2015;202. Available from: https://dx.doi.org/10.1016/j.virusres.2014.11.021

39. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun . 2020;11(1). Available from: https://dx.doi.org/10.1038/s41467-020-15562-9

40. Fehr A., Perlman S. Coronaviruses: An Overview of Their Replication and Pathogenesis. methods in Molecular Biology. Coronaviruses Methods Protoc . 2015;1282(1). Available from: https://doi.org/10.1007/978-1-4939-2438-7_1

41. Hidayani WR. Faktor Faktor Risiko Yang Berhubungan Dengan COVID 19 : Literature Review. J Untuk Masy Sehat. 2020;4(2).

42. Yang W, Yan F. Patients with RT-PCR-confirmed COVID-19 and normal chest CT. Vol. 295, Radiology. 2020.

43. Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J, et al. Neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 inpatients and convalescent patients. Clin Infect Dis . 2020;71(10). Available from: https://dx.doi.org/10.1093/cid/ciaa721

44. Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo CW, Susilo A, et al. Pedoman Tatalaksana COVID-19. 4th ed. Perhimpunan Dokter Paru Indonesia; 2022.

45. Mejía F, Medina C, Cornejo E, Morello E, Vásquez S, Alave J, et al. Oxygen saturation as a predictor of mortality in hospitalized adult patients with COVID-19 in a public hospital in Lima, Peru. PLoS One. 2020;15(12 December).

46. Sandor-Keri J, Benedek I, Polexa S, Benedek I. The link between SARS-CoV-2 infection, inflammation and hypercoagulability-impact of hemorheologic alterations on cardiovascular mortality. Vol. 10, Journal of Clinical Medicine. 2021.

47. Pourbagheri-Sigaroodi A, Bashash D, Fateh F, Abolghasemi H. Laboratory findings in COVID-19 diagnosis and prognosis. Vol. 510, Clinica Chimica Acta. 2020.

48. Mus R, Thaslifa T, Abbas M, Sunaidi Y. Studi Literatur: Tinjauan Pemeriksaan Laboratorium pada Pasien COVID-19. J Kesehat Vokasional.

2021;5(4).

49.   Sakka M, Connors JM, Hékimian G, Martin-Toutain I, Crichi B, Colmegna I, et al. Association between D-Dimer levels and mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and pooled analysis. Vol. 45, JMV-Journal de Medecine Vasculaire. 2020.

50.   Long H, Nie L, Xiang X, Li H, Zhang X, Fu X, et al. D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis. Biomed Res Int. 2020;2020.

51.   Paliogiannis P, Mangoni AA, Dettori P, Nasrallah GK, Pintus G, Zinellu A. D-dimer concentrations and covid-19 severity: A systematic review and meta-analysis. Vol. 8, Frontiers in Public Health. 2020.

52.   Liu F, Li L, Xu M Da, Wu J, Luo D, Zhu YS, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127.

53.   Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Vol. 505, Clinica Chimica Acta. 2020.

54.   Yan ST, Sun LC, Jia HB, Gao W, Yang JP, Zhang GQ. Procalcitonin levels in bloodstream infections caused by different sources and species of bacteria. Am J Emerg Med. 2017;35(4).

55.   Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect . 2020;53(3). Available from: https://dx.doi.org/10.1016/j.jmii.2020.02.012

56.   Burhan E, Isbaniah F, Susanto AD, Aditama TY, Soedarsono. Diagnosis dan Penatalaksanaan Pneumonia COVID-19. Vol. 1, Perhimpunan Dokter Paru Indonesia. 2020.

57.   Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo CW, Susilo A, et al. Pedoman Tatalaksana Covid-19. 1st ed. Perhimpunan Dokter Paru Indonesia; 2020.

58.   Badan Pengawasan Obat dan Makanan Republik Indonesia. Informatorium

Obat Covid-19 di Indonesia. 3rd ed. Jakarta: Badan Pengawasan Obat dan Makanan Republik Indonesia; 2021.

59.   Perhimpunan Dokter Spesialis Farmakologi Klinik Indonesia. Kajian Farmakoterapi Pengobatan COVID-19. Jakarta: Perdafki; 2020.

60.   Kahwa I, Nyarko RO, Boateng E, Boateng PO. a Comparison Analysis on Remdesivir, Favipiravir, Hydroxychloroquine, Chloroquine and Azithromycin in the Treatment of Corona Virus Disease 2019 (Covid-19)-a Review. Nyarko al World J Pharm Pharm Sci . 2020;9(121). Available from: http://dx.doi.org/10.20959/wjpps20205-16143

61.   Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA - J Am Med Assoc. 2020;323(18). Available from: https://dx.doi.org/10.1001/jama.2020.6019

62.   Sultana J, Cutroneo PM, Crisafulli S, Puglisi G, Caramori G, Trifirò G. Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines. Drug Saf . 2020;43(8). Available from: https://dx.doi.org/10.1007/s40264-020-00976-7

63.   Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet . 2020;395(10223). Available from: https://dx.doi.org/10.1016/S0140-6736(20)30183-5

64.   Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev . 2010;23(3). Available from: https://dx.doi.org/10.1128/CMR.00078-09

65.   Cramer CL, Patterson A, Alchakaki A, Soubani AO. Immunomodulatory indications of azithromycin in respiratory disease: a concise review for the clinician. Postgrad Med. 2017;129(5). Available from: https://dx.doi.org/10.1080/00325481.2017.1285677

66.   Parnham MJ, Haber VE, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R. Azithromycin: Mechanisms of action and their relevance for clinical applications. Pharmacol Ther . 2014;143(2). Available from: https://dx.doi.org/10.1016/j.pharmthera.2014.03.003

67. Masturoh I, T. NA. Metodologi Penelitian Kesehatan. Kementrian Kesehatan Republik Indonesia; 2018.

68. Komisi Penanganan Covid-19 dan Pemulihan Ekonomi Nasional (KPCPEN). Peta Sebaran Covid-19 . 2020 [cited 2022 Jan 9]. Available from: https://covid19.go.id/peta-sebaran

69. Duhri AP, Jabbar R, Yunus N. Karakteristik Pasien Konfirmasi Covid-19 Di Rsud Lamaddukkelleng Kabupaten Wajo (Tinjauan Pasien Periode Maret-September 2020). Media Kesehat Politek Kesehat Makassar. 2020;15(2).

70. Lisni I, Mujianti D, Anggriani A. Antibiotic Profile For Covid-19 Treatment In A Hospital In Bandung Article History. J Ilm Farm Bahari . 2021;12(2).

71. Ariyani H, Fitriani S, Rahmah S. Profil Penggunaan Obat pada Pasien COVID-19 di Rumah Sakit Umum Daerah Ulin Banjarmasin. J Pharmascience. 2021;8(2).

72. Khaerunnisa R, Aula Rumana N, Yulia N, Fannya P, Studi P, Medis R, et al. Gambaran karakteristik pasien COVID-19 di Rumah Sakit Mekar Sari Bekasi tahun 2020-2021. J Manaj Inf Kesehat Indones. 2022;10(1).

73. Hu B, Guo H, Zhou P, Shi Z-L. Author Correction: Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2022;20(5).

74. Maharianingsih NM, Sudirta IK, Suryaningsih NPA. Karakteristik Pasien dan Penggunaan Obat Pada Pasien Covid-19 Derajat Sedang-Berat di RSUD Karangasem. Indones J Pharm Educ. 2022;2(2):86–94.

75. Fata UH, Febriana L. Oxygen Saturation (SPO2) in Covid-19 Patients. J Ners dan Kebidanan (Journal Ners Midwifery). 2021;8(3).

76. Wang Y, Lu X, Li Y, Chen H, Chen T, Su N, et al. Clinical course and outcomes of 344 intensive care patients with COVID-19. Vol. 201, American Journal of Respiratory and Critical Care Medicine. 2020.

77. Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents. 2020;56(2).

78. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with covid-19: Evidence from meta-analysis. Aging (Albany NY).

2020;12(7).

79. Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 Diabetes and its Impact on the Immune System. Curr Diabetes Rev. 2019;16(5).

80. Kusumawardhani N. Evaluasi Penggunaan Obat Antituberkulosis pada Pasien Rawat Jalan di Rumah Sakit Paru Sindawangi Jawa Barat Periode Januari-Juni 2015. Naskah Publ FKIK UMY. 2016;

81. Maryati W, Widyastuti A, Rizky APK, Listyorini PI, Aryanti FD. Analisis Karakteristik Pada Pasien Rawat Inap Kasus Covid-19. J Ilm Rekam Medis dan Inform Kesehat. 2022;12(1).

82. Ilpaj SM, Nurwati N. ANALISIS PENGARUH TINGKAT KEMATIAN AKIBAT COVID-19 TERHADAP KESEHATAN MENTAL MASYARAKAT DI INDONESIA. Focus J Pekerj Sos. 2020;3(1).

83. Hikmawati I, Setiyabudi R. Epidemiology of COVID-19 in Indonesia: common source and propagated source as a cause for outbreaks. J Infect Dev Ctries. 2021;15(5).

84. Khanmohammadi S, Rezaei N. Role of Toll-like receptors in the pathogenesis of COVID-19. Vol. 93, Journal of Medical Virology. 2021.

85. Saxena S, Manchanda V, Sagar T, Nagi N, Siddiqui O, Yadav A, et al. Clinical characteristic and epidemiological features of SARS CoV-2 disease patients from a COVID-19 designated hospital in New Delhi. J Med Virol. 2021;93(4).

86. Li S, Lund JB, Christensen K, Baumbach J, Mengel-From J, Kruse T, et al. Exploratory analysis of age and sex dependent DNA methylation patterns on the X-chromosome in whole blood samples. Genome Med. 2020;12(1).

87. Strindhall J, Skog M, Ernerudh J, Bengner M, Löfgren S, Matussek A, et al. The inverted CD4/CD8 ratio and associated parameters in 66-year-old individuals: The Swedish HEXA immune study. Age (Omaha). 2013;35(3).

88. Wenham C, Smith J, Morgan R. COVID-19: the gendered impacts of the outbreak. Vol. 395, The Lancet. 2020.

89. Yulia R, Ikasanti PAI, Herawati F, Hartono R, Hanum PS, Lestiono, et al. Evaluation of Antibacterial and Antiviral Drug Effectiveness in COVID-19 Therapy: A Data-Driven Retrospective Approach. Pathophysiology.

2022;29(1).

90. Surendra H, Elyazar IR, Djaafara BA, Ekawati LL, Saraswati K, Adrian V, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. Lancet Reg Heal - West Pacific. 2021;9.

91. Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older adults. Vol. 7, Therapeutic Advances in Drug Safety. 2016.

92. Bunyavanich S, Do A, Vicencio A. Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults. Vol. 323, JAMA - Journal of the American Medical Association. 2020.

93. C.M. P, L. O, L.I. H, H. R, Y. C, K.A. T, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study. BMJ. 2020;369.

94. Chatterjee NA, Jensen PN, Harris AW, Nguyen DD, Huang HD, Cheng RK, et al. Admission respiratory status predicts mortality in COVID-19. Influenza Other Respi Viruses. 2021;15(5).

95. Bastug A, Aslaner H, Aybar Bilir Y, Kemirtlek N, Gursoy FM, Bastug S, et al. Multiple system inflammatory syndrome associated with SARS-CoV-2 infection in an adult and an adolescent. Vol. 41, Rheumatology International. 2021.

96. Li J, Liu Z, Wu G, Yi M, Chen Y, Li K, et al. D-Dimer as a Prognostic Indicator in Critically Ill Patients Hospitalized With COVID-19 in Leishenshan Hospital, Wuhan, China. Front Pharmacol. 2020;11.

97. Song X, Ji J, Reva B, Joshi H, Calinawan AP, Mazumdar M, et al. Post-Anticoagulant D-Dimer Is a Highly Prognostic Biomarker of COVID-19 Mortality. SSRN Electron J. 2021;

98. Moreno G, Carbonell R, Bodí M, Rodríguez A. Systematic review of the prognostic utility of D-dimer, disseminated intravascular coagulation, and anticoagulant therapy in COVID-19 critically ill patients. Med Intensiva. 2021;45(1).

99. Xu J bo, Xu C, Zhang R bing, Wu M, Pan C kun, Li X jie, et al. Associations of procalcitonin, C-reaction protein and neutrophil-to-

lymphocyte ratio with mortality in hospitalized COVID-19 patients in China. Sci Rep. 2020;10(1).

100. Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. Vol. 64, Intervirology. 2021.

101. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;36(7).

102. Dehelean CA, Lazureanu V, Coricovac D, Mioc M, Oancea R, Marcovici I, et al. SARS-CoV-2: Repurposed drugs and novel therapeutic approaches— insights into chemical structure—biological activity and toxicological screening. Vol. 9, Journal of Clinical Medicine. 2020.

103. Dabbous HM, Abd-Elsalam S, El-Sayed MH, Sherief AF, Ebeid FFS, El Ghafar MSA, et al. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Arch Virol . 2021;166(3). Available from: https://dx.doi.org/10.1007/s00705-021-04956-9

104. Solaymani-Dodaran M, Ghanei M, Bagheri M, Qazvini A, Vahedi E, Hassan Saadat S, et al. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. Int Immunopharmacol. 2021;95.

105. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020;6(10).

106. Kokturk N, Babayigit C, Kul S, Duru Cetinkaya P, Atis Nayci S, Argun Baris S, et al. The predictors of COVID-19 mortality in a nationwide cohort of Turkish patients. Respir Med. 2021;183.

107. Rawson TM, Zhu N, Ranganathan N, Gilchrist M, Satta G, Cooke G, et al. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing Timothy. Clin Infect Dis. 2020;71(9).

108. Ghosh S, Bornman C, Zafer MM. Antimicrobial Resistance Threats in the emerging COVID-19 pandemic: Where do we stand? Vol. 14, Journal of Infection and Public Health. 2021.

109. Bogdanić N, Močibob L, Vidović T, Soldo A, Begovać J. Azithromycin consumption during the COVID- 19 pandemic in Croatia, 2020. PLoS One. 2022;17(2 February).

110. Getahun H, Smith I, Trivedi K, Paulin S, Balkhy HH. Tackling antimicrobial resistance in the COVID-19 pandemic. Vol. 98, Bulletin of the World Health Organization. 2020.

111. Egyir B, Obeng-Nkrumah N, Kyei GB. COVID-19 pandemic and antimicrobial resistance: Another call to strengthen laboratory diagnostic capacity in Africa. Afr J Lab Med. 2020;9(1).

112. Buetti N, Mazzuchelli T, Lo Priore E, Balmelli C, Llamas M, Pallanza M, et al. Early administered antibiotics do not impact mortality in critically ill patients with COVID-19. Vol. 81, Journal of Infection. 2020.

113. Uyaroğlu OA, Sönmezer MÇ, Telli Dizman G, Çalık Başaran N, Karahan S, Uzun Ö. Comparison of Favipiravir to Hydroxychloroquine Plus Azithromycin in the Treatment of Patients with Non-critical COVID-19: A Single-center, Retrospective, Propensity Score-matched Study. Acta Medica Cordoba. 2022;53(1).

114. Donsu YC, Hasmono D. Tinjauan Azitromisin Pada Penyakit Virus Korona 2019 (COVID-19). Pharmacon J Farm Indones. 2020;17(2).

115. Ivashchenko AA, Dmitriev KA, Vostokova N V., Azarova VN, Blinow AA, Egorova AN, et al. AVIFAVIR for Treatment of Patients with Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clin Infect Dis. 2021;73(3).